tt factor - company presentation

Media&ng rela&ons with industry

Company presenta&on July 2011

FOCUSING THE MODEL

IFOM and IEO joined forces to create in June 2010 a tech transfer opera-on which could also support business development for drug discovery and other transla&onal programs

IFOM and IEO at glance

•  Since mid 2009, IEO has started an industry standard drug discovery program (DDP);

•  The IFOM-‐IEO Campus is one of Europe’s largest research campus dedicated to Cancer Research with over 400 scien&sts and 4 PhD programs with 150 PhD students;

•  The IEO is a private research hospital with 320 MD and PhDs dedicated to preven&on, early diagnosis and therapy of cancer through advanced technology and medical prac&ces;

TTFactor MISSION

Help IFOM and IEO improving and increasing solu7ons to medical needs of pa7ents while funding their research

Advance scien7fic results arising from the IFOM and IEO by suppor7ng the genera7on, protec7on and transfer of intellectual proper7es and know how to the for profit sector through:

– Technology licensing (Confiden7ality Ag., Term sheet, Due diligence);

– Sponsored research agreements;

– MTA (Material transfer Agreements);

– and spin off crea7on.

TEAM Daniela Bellomo PhD MBA General Management Mario Cesana MSc (Econ) Chief Financial Officer Germano Ferrari PhD MBA Business Development Marzia Fumagalli PhD Intellectual Property Marilina Palmiotto LLP Legal Jacopo Franchini BSc Business Development

Associate Aurelia Ramunni Assistant

BOARD OF DIRECTORS

Pier Giuseppe Pelicci, President - IEO Claudio Basilico - New York University Andrea Cuomo - ST Microelectronics Marco Foiani - IFOM Isaac Kohlberg - Harvard University Tomas Lindhal - FRS-Cancer Research UK Stefano Michelini - IEO Elisabetta Petrucci - FIRC Domenico Triarico - IEO Raffaela Zoboli - IFOM

ACTIVITIES

PATENTING

MARKETING

LICENSING

SPONSORED RESEARCH

SPINOFFS

EDUCATIONAL CAMPAIGN ON IP

SUPPORT INTERNAL OFFICES IN IP ISSUES

BUSINESS DEVELOPMENT FOR DDP

FOCUSED TOWARDS EXTERNAL

STAKEHOLDERS

FOCUSED TOWARDS INTERNAL

STAKEHOLDERS

PATENT PORTFOFLIO AVAILABLE FOR LICENSING

Subject Inves-gators Filed Descrip-on

Biomarkers Pier Paolo Di Fiore at al. 2004 A novel cancer “signature” (10 genes or 80 genes) which helps to predict the course of disease and the choice of treatment in early stages of Lung Cancer

Biomarkers Pier Paolo Di Fiore at al. 2005 Method for establishing suscep&bility to drug treatment in breast cancer for drugs ac&ng on Numb gene (GRANTED IN USA)

Small Molecules Peter De Wulf et al. 2009 Novel an&-‐cancer compounds with an&tubulin effect

Small Molecules Saverio Minucci et al. 2010 Novel compounds with an&-‐tumor effect inhibi&ng LSD1 and LSD2 histone demethylases for the treatment of tumors and viral infec&ons

Tumor Immunotherapy Maria Rescigno et al. 2010 Method to improve the tumoral an&gen presenta&on to dendri&c cells by Salmonella infec&on for melanoma therapy or prophylaxis

Screening Assay Ario De Marco et al. 2010 Assay for iden&fying agents ac&ng on cell growth (through eIF6)

Biologics Nicolai Sidenius 2010 A novel “dual ac&on” type of inhibitor of the urokinase-‐type plasminogen ac&vator receptor (uPAR)

Biomarkers Pier Paolo Di Fiore at al. 2010 A serum circula&ng miRNAs diagnos&c test to iden&fy asymptoma&c high-‐risk individuals with early stages lung cancer (NSCLC)

Diagnos-cs Marco Chinol et al. 2010 Novel radiopharmaceu&cals with an extended half-‐life for cancer diagnosis and therapy

Please visit our web site www.ttfactor.com to look for new patent opportunities

Visit us at www.cactor.com Contact us at TTFactor s.r.l.

Via Adamello, 16 20139 Milano T: +39 02 94375140 F +39 02 94375991

e-mail: [email protected]